H Grasemann1, E Tullis, F Ratjen. 1. Division of Respiratory Medicine, Department of Pediatrics, the Hospital for Sick Children, University of Toronto, Toronto, Canada. hartmut.grasemann@sickkids.ca
Abstract
BACKGROUND: Cystic fibrosis (CF) airways are nitric oxide (NO) deficient. We studied safety and efficacy of repeated inhalations of nebulized L-arginine, the substrate for NO synthase (NOS), in patients with CF. METHODS: Double-blind, randomized, placebo-controlled crossover treatment trial of twice daily inhalation of 500 mg L-arginine for two weeks compared to inhalation of saline in 19 CF patients (ClinicalTrials.gov Identifier: NCT00405665). RESULTS:L-arginine inhalation was well tolerated and resulted in a significant increase in exhaled NO. FEV1 increased by an average of 56 ml compared to -8 ml after saline solution; but this difference did not reach statistical significance. Sputum concentrations of L-ornithine, the product of arginase activity, increased significantly while the L-ornithine derived polyamines did not. There was no change in inflammatory markers in sputum. CONCLUSION: Repeated inhalation of L-arginine in CF patients was safe and well tolerated. Inhaled L-arginine increased NO production without evidence for changes in airway inflammation.
RCT Entities:
BACKGROUND:Cystic fibrosis (CF) airways are nitric oxide (NO) deficient. We studied safety and efficacy of repeated inhalations of nebulized L-arginine, the substrate for NO synthase (NOS), in patients with CF. METHODS: Double-blind, randomized, placebo-controlled crossover treatment trial of twice daily inhalation of 500 mg L-arginine for two weeks compared to inhalation of saline in 19 CFpatients (ClinicalTrials.gov Identifier: NCT00405665). RESULTS:L-arginine inhalation was well tolerated and resulted in a significant increase in exhaled NO. FEV1 increased by an average of 56 ml compared to -8 ml after saline solution; but this difference did not reach statistical significance. Sputum concentrations of L-ornithine, the product of arginase activity, increased significantly while the L-ornithine derived polyamines did not. There was no change in inflammatory markers in sputum. CONCLUSION: Repeated inhalation of L-arginine in CFpatients was safe and well tolerated. Inhaled L-arginine increased NO production without evidence for changes in airway inflammation.
Authors: M Kolpen; T Bjarnsholt; C Moser; C R Hansen; L F Rickelt; M Kühl; C Hempel; T Pressler; N Høiby; P Ø Jensen Journal: Clin Exp Immunol Date: 2014-07 Impact factor: 4.330
Authors: Kasper N Kragh; Morten Alhede; Peter Ø Jensen; Claus Moser; Thomas Scheike; Carsten S Jacobsen; Steen Seier Poulsen; Steffen Robert Eickhardt-Sørensen; Hannah Trøstrup; Lars Christoffersen; Hans-Petter Hougen; Lars F Rickelt; Michael Kühl; Niels Høiby; Thomas Bjarnsholt Journal: Infect Immun Date: 2014-08-11 Impact factor: 3.441
Authors: Christine M Hochstedler; Mariah R Leidinger; Mary T Maher-Sturm; Katherine N Gibson-Corley; David K Meyerholz Journal: J Histotechnol Date: 2013-12 Impact factor: 0.714